Your session is about to expire
← Back to Search
Behavioral Intervention
Motivational Interviewing for HIV/AIDS and Alcohol Use
N/A
Waitlist Available
Led By Amy C Justice, MD, PhD
Research Sponsored by Yale University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline and 30 days post intervention
Awards & highlights
No Placebo-Only Group
Summary
This trial is designed for HIV patients who are on multiple medications and consume alcohol. It aims to help them manage symptoms caused by the interaction between alcohol and their medications.
Who is the study for?
This trial is for HIV patients who are part of the VACS and MASH studies, take 5 or more medications, and have consumed alcohol in the last month. They must not have been diagnosed with a severe alcohol use disorder in the past year.
What is being tested?
The HARP study tests a brief intervention combining Information-Motivation-Behavioral Skills (IMB) with motivational interviewing techniques to address symptoms affected by alcohol and medication interactions in HIV patients.
What are the potential side effects?
While specific side effects aren't listed for this behavioral intervention, participants may experience discomfort discussing personal habits like medication use and alcohol consumption.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline and 30 days post intervention
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline and 30 days post intervention
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
HIV Vaccine
Body Weight Changes
Number of Medications Prescribed Post Intervention
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: HIV Medications and Alcohol UseExperimental Treatment1 Intervention
Participants with HIV who take 5 or more medications and currently (within the past month) consume alcohol
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
IMB-motivational interviewing (MI) techniques (IMB-MI)
2023
N/A
~50
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for alcoholism include pharmacologic agents like naltrexone, acamprosate, and disulfiram, as well as psychosocial interventions such as cognitive-behavioral therapy (CBT) and brief interventions. Naltrexone works by blocking opioid receptors, reducing the rewarding effects of alcohol, while acamprosate modulates glutamate neurotransmission to stabilize brain activity.
Disulfiram inhibits the enzyme acetaldehyde dehydrogenase, causing unpleasant reactions when alcohol is consumed. Psychosocial interventions like CBT help patients identify and cope with high-risk situations, and brief interventions focus on immediate behavioral changes.
These treatments are crucial as they address both the biological and behavioral aspects of alcoholism, improving overall treatment outcomes and reducing adverse symptoms from alcohol-medication interactions.
Variance in the Efficacy of Brief Interventions to Reduce Hazardous and Harmful Alcohol Consumption Between Injury and Noninjury Patients in Emergency Departments: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Therapy preference and treatment outcome in clients with mild to moderate alcohol dependence.Alcohol treatment effects on secondary nondrinking outcomes and quality of life: the COMBINE study.
Variance in the Efficacy of Brief Interventions to Reduce Hazardous and Harmful Alcohol Consumption Between Injury and Noninjury Patients in Emergency Departments: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Therapy preference and treatment outcome in clients with mild to moderate alcohol dependence.Alcohol treatment effects on secondary nondrinking outcomes and quality of life: the COMBINE study.
Find a Location
Who is running the clinical trial?
National Institute on Alcohol Abuse and Alcoholism (NIAAA)NIH
839 Previous Clinical Trials
1,083,598 Total Patients Enrolled
Yale UniversityLead Sponsor
1,930 Previous Clinical Trials
3,033,408 Total Patients Enrolled
Amy C Justice, MD, PhDPrincipal InvestigatorYale University
1 Previous Clinical Trials
100 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am in the VACS and MASH studies, take 5+ medications, and either have a positive alcohol test or report current drinking.
Research Study Groups:
This trial has the following groups:- Group 1: HIV Medications and Alcohol Use
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.